tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

UTHR Stock Latest News

Liquidia assumed with a Buy at Jefferies
The FlyLiquidia assumed with a Buy at Jefferies
4d ago
LQDA
UTHR
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for Pulmonary Fibrosis
PremiumCompany Announcements
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for Pulmonary Fibrosis
5d ago
UTHR
United Therapeutics price target raised to $415 from $385 at UBS
PremiumThe Fly
United Therapeutics price target raised to $415 from $385 at UBS
6d ago
UTHR
United Therapeutics’ Promising Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis
PremiumCompany Announcements
United Therapeutics’ Promising Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis
7d ago
UTHR
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis: A Potential Game-Changer
PremiumCompany Announcements
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis: A Potential Game-Changer
11d ago
UTHR
United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment
PremiumCompany AnnouncementsUnited Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment
12d ago
UTHR
DDD Lawsuit Alert! Class Action Lawsuit Against 3D Systems Corporation
Premium
Market News
DDD Lawsuit Alert! Class Action Lawsuit Against 3D Systems Corporation
12d ago
DDD
UTHR
United Therapeutics Launches $1 Billion Share Buyback
Premium
Company Announcements
United Therapeutics Launches $1 Billion Share Buyback
17d ago
8K
UTHR
United Therapeutics up 7%, Liquidia down 9% in afternoon trading
PremiumThe Fly
United Therapeutics up 7%, Liquidia down 9% in afternoon trading
17d ago
LQDA
UTHR
United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment
PremiumCompany Announcements
United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment
18d ago
UTHR
United Therapeutics Advances in Pulmonary Fibrosis Treatment with Phase 3 Study
PremiumCompany Announcements
United Therapeutics Advances in Pulmonary Fibrosis Treatment with Phase 3 Study
18d ago
UTHR
United Therapeutics’ PAH Study Update: Implications for Investors
PremiumCompany Announcements
United Therapeutics’ PAH Study Update: Implications for Investors
18d ago
UTHR
Buy Rating for United Therapeutics Driven by Anticipated Growth in IPF Market and Strong Market Position
PremiumRatingsBuy Rating for United Therapeutics Driven by Anticipated Growth in IPF Market and Strong Market Position
18d ago
UTHR
United Therapeutics announces $1B accelerated share repurchase program
Premium
The Fly
United Therapeutics announces $1B accelerated share repurchase program
18d ago
UTHR
United Therapeutics Reports Record Revenue and Growth
Premium
Company Announcements
United Therapeutics Reports Record Revenue and Growth
18d ago
UTHR
Hold Rating for United Therapeutics Amid Mixed Tyvaso Performance and Competitive Challenges
PremiumRatings
Hold Rating for United Therapeutics Amid Mixed Tyvaso Performance and Competitive Challenges
19d ago
UTHR
United Therapeutics: Hold Rating Amid Uncertain Competitive Pressures and Awaiting Key Data
PremiumRatings
United Therapeutics: Hold Rating Amid Uncertain Competitive Pressures and Awaiting Key Data
19d ago
UTHR
Optimistic Buy Rating for United Therapeutics Driven by Promising TETON Trial Prospects for Tyvaso in IPF Market
PremiumRatings
Optimistic Buy Rating for United Therapeutics Driven by Promising TETON Trial Prospects for Tyvaso in IPF Market
19d ago
UTHR
United Therapeutics price target lowered to $400 from $425 at H.C. Wainwright
PremiumThe Fly
United Therapeutics price target lowered to $400 from $425 at H.C. Wainwright
19d ago
UTHR
Cautious Hold Rating on United Therapeutics Amid TETON Study Skepticism and Competitive Risks
PremiumRatingsCautious Hold Rating on United Therapeutics Amid TETON Study Skepticism and Competitive Risks
19d ago
UTHR
United Therapeutics Reports Record Q2 2025 Financial Results
Premium
Company Announcements
United Therapeutics Reports Record Q2 2025 Financial Results
19d ago
UTHR
United Therapeutics: Strong Growth Potential and Strategic Moves Justify Buy Rating
Premium
Ratings
United Therapeutics: Strong Growth Potential and Strategic Moves Justify Buy Rating
19d ago
UTHR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >